Hong Kong, 9 April 2026—HUTCHMED (China) Limited will present pre-clinical and early-phase clinical findings for multiple in-house oncology compounds at the American Association of Cancer Research (AACR) Annual Meeting 2026, scheduled for 17–22 April in San Diego.

HMPL-A580: first-in-class ATTC • The company will disclose pre-clinical data on HMPL-A580, a PI3K/PiKK inhibitor payload conjugated to an anti-EGFR antibody via a cleavable linker (Poster #4549, 21 April). • The payload inhibited PI3K and PIKK family kinases with IC₅₀ values of 1–10 nM and showed high selectivity in a 418-kinase panel. • Upon binding EGFR-positive tumour cells, HMPL-A580 underwent rapid internalisation, lysosomal trafficking and payload release, leading to apoptosis through PAM and PIKK pathway blockade. • In a 38-line solid-tumour panel, growth inhibition was strongest in EGFR-high, EGFR-mutant or PAM-altered cells; a pronounced bystander effect emerged when EGFR-negative cells were co-cultured with EGFR-positive cells. • Weekly intravenous dosing at 1–10 mg/kg for two weeks generated dose-dependent tumour suppression in multiple xenograft models, outperforming antibody or payload monotherapy. • The conjugate was stable in plasma from humans, monkeys, rats and mice, and exhibited favourable pharmacokinetics in cynomolgus monkeys.

Surufatinib combination studies • Updated Phase Ib/II data on surufatinib plus sintilimab and capecitabine in previously treated metastatic small-bowel adenocarcinoma and appendiceal carcinoma will be shown (Poster #CT160, 20 April). • An exploratory two-cohort Phase II study evaluating sequential surufatinib with gemcitabine and nab-paclitaxel (AG) versus AG alone after a six-week AG induction in locally advanced or metastatic pancreatic ductal adenocarcinoma will also be presented (Poster #CT146, 20 April).

Strategic context HUTCHMED’s Antibody-Targeted Therapy Conjugate (ATTC) platform fuses monoclonal antibodies with proprietary small-molecule inhibitor payloads to enhance tumour-specific delivery and mitigate systemic toxicity. HMPL-A580 is the second ATTC candidate derived from the company’s novel PI3K/PiKK inhibitor payload series.

Surufatinib, HUTCHMED’s marketed angio-immuno kinase inhibitor (brand name SULANDA® in China), targets VEGFR, FGFR and CSF-1R. The new datasets aim to clarify its potential in combination regimens across difficult-to-treat gastrointestinal malignancies.

All presentations will be delivered during AACR’s poster sessions; no financial metrics or regulatory timelines were disclosed in the announcement.